Evicenter
Linzess (linaclotide) in Irritable bowel syndrome with constipation
Manufacturer
AbbVie, Inc.; Ironwood Pharmaceuticals, Inc.
Prescribing information
Linzess (opens in a new tab)
Questions
19
Last updated

All questions

Safety: Linzess (linaclotide) in irritable bowel syndrome with constipation

6 questions · 2 sources

Side effects

What are the most common side effects of Linzess for IBS-C in adults?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

Note: Table 1 columns are LINZESS 290 mcg (N=807) and placebo (N=798), in that order (% of patients). The figure of more than 2,200 adults on the safety page includes placebo-treated patients and Trial 6 (the label's geriatric use section counts 2219 IBS-C patients in Trials 1, 2, and 6); Table 1 is from Trials 1 and 2.

How common is diarrhea with Linzess in adults with IBS-C?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

How many adults with IBS-C stopped Linzess because of side effects?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

In long-term Linzess IBS-C trials, how often did side effects lead to dose reduction?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

What less common side effects were reported with Linzess in adults with IBS-C?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

What are the side effects of Linzess in children with IBS-C?

Applies to Irritable bowel syndrome with constipation (IBS-C) in pediatric patients 7 years of age and older

Note: 290 mcg is higher than the recommended pediatric IBS-C dosage of 145 mcg once daily (see the IBS-C dose question).